Circulating angiopoietin-2 in essential hypertension: Relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/ pravastatin

Journal of Hypertension

Volumn 27, Issue 8, 2009, Pages 1641-1647

  David, Sascha ^a   Kümpers, Philipp ^a   Lukasz, Alexander ^a   Kielstein, Jan T ^a   Haller, Hermann ^a   Fliser, Danilo ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

3 hydroxy 3 methyl glutaryl CoA reductase inhibitor; Angiopoietin 2; Angiotensin II receptor blocker; Arterial hypertension; Atherosclerosis; Inflammation markers; Inter cellular adhesion molecule 1; Olmesartan; Statin; Vascular cell adhesion molecule 1

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANGIOPOIETIN 2; ANGIOTENSIN II; BIOLOGICAL MARKER; FOCAL ADHESION KINASE 1; HYDROCHLOROTHIAZIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; OLMESARTAN; PLACEBO; PRAVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ADD ON THERAPY; ADULT; ARTICLE; ATHEROSCLEROSIS; BEDTIME DOSAGE; BLOOD PRESSURE MEASUREMENT; CELL ACTIVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULITIS;

EID: 66249121829     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832be575     Document Type: Article

References (36)

1. Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care 2008; 31(Suppl 2):S215-S221.
2. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
4. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
5. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108:2993-2999.
6. Goldschmidt-Clermont PJ, Creager MA, Losordo DW, Lam GK, Wassef M, Dzau VJ. Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation 2005; 112:3348-3353.
7. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
8. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100:158-173.
9. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007; 100:174-190.
10. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27:552-558.
11. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1in vascular protection. Circ Res 2006; 98:1014-1023.
12. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res 2000; 86:24-29.
13. Hughes DP, Marron MB, Brindle NP. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappa B inhibitor ABIN-2. Circ Res 2003; 92:630-636.
14. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-239.
15. Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, Haller H, Kumpers P. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care 2008; 12:R94.
16. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005; 180:113-118.
17. Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003; 107:1308-1314.
18. Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 2005; 258:336-343.
19. Patel JV, Lim HS, Varughese Gl, Hughes EA, Lip GY. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 2008; 40:215-222.
20. Kumpers P, Hellpap J, David S, Horn R, Leitolf R, Haller H, Haubitz M. Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrol Dial Transplant 2009. [Epub ahead of print], doi: 10.1093/ndt/gfn755.
21. David S, Kumpers P, Hellpap J, Horn R, Leitolf H, Haller H, Kielstein JT. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis 2009. [Epub ahead of print], doi: 10.1053.j.ajkd.2008.11.030.
22. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110:2355-2360.
23. Kumpers P, Koenecke C, Hecker H, Hellpap J, Horn R, Verhagen W, et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem-cell transplantation in patients with high-risk myeloid malignancies. Blood 2008; 112:2139-2148.
24. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
25. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003; 88:4496-4501.
26. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
27. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42:905-910.
28. Khan BV, Navalkar S, Khan QA, Rahman ST, Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 2001; 38:1662-1667.
29. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108:2292-2297.
30. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70.
31. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106:1447-1452.
32. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933-1935.
33. Yamakuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, Talbot-Fox K, et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 2005; 96:1185-1192.
34. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110:1103-1107.
35. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, Rifai N. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47:418-425.
36. Tadros A, Hughes DP, Dunmore BJ, Brindle NP. ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1. Blood 2003; 102:4407-4409.